North America Anti-hypertensive Drugs Market Size & Outlook

The anti-hypertensive drugs market in North America is expected to reach a projected revenue of US$ 11,102.4 million by 2030. A compound annual growth rate of 3.3% is expected of North America anti-hypertensive drugs market from 2024 to 2030.
Revenue, 2023 (US$M)
$8,851.4
Forecast, 2030 (US$M)
$11,102.4
CAGR, 2024 - 2030
3.3%
Report Coverage
North America

North America anti-hypertensive drugs market, 2018-2030 (US$M)

North

North America anti-hypertensive drugs market highlights

  • The North America anti-hypertensive drugs market generated a revenue of USD 8,851.4 million in 2023.
  • The market is expected to grow at a CAGR of 3.3% from 2024 to 2030.
  • In terms of segment, primary hypertension was the largest revenue generating type in 2023.
  • Secondary Hypertension is the most lucrative type segment registering the fastest growth during the forecast period.
  • Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.


North America data book summary

Market revenue in 2023USD 8,851.4 million
Market revenue in 2030USD 11,102.4 million
Growth rate3.3% (CAGR from 2023 to 2030)
Largest segmentPrimary hypertension
Fastest growing segmentSecondary Hypertension
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPrimary Hypertension, Secondary Hypertension
Key market players worldwideSanofi SA, Boehringer Ingelheim Pharma, Novartis AG ADR, Johnson & Johnson, Daiichi Sankyo Co Ltd, Merck & Co Inc, AstraZeneca PLC, Pfizer Inc, Lupin, Sun Pharmaceutical Industries


Other key industry trends

  • In terms of revenue, North America region accounted for 37.5% of the global anti-hypertensive drugs market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 9,442.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Anti-hypertensive Drugs Market Scope

Anti-hypertensive drugs market segmentation & scope
Primary Hypertension
Secondary Hypertension
Diuretics
ACE Inhibitors
Calcium Channel Blockers
Beta-adrenergic Blockers
Vasodilators
Others Drug Classes
Oral
Injectables
Other Route of Administration
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy

Anti-hypertensive Drugs Market Companies

Name Profile # Employees HQ Website

North America anti-hypertensive drugs market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-hypertensive drugs market will help companies and investors design strategic landscapes.


Primary hypertension was the largest segment with a revenue share of 71.54% in 2023. Horizon Databook has segmented the North America anti-hypertensive drugs market based on primary hypertension, secondary hypertension covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to North America anti-hypertensive drugs market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of North America anti-hypertensive drugs market databook

  • Our clientele includes a mix of anti-hypertensive drugs market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the North America anti-hypertensive drugs market, including forecasts for subscribers. This continent databook contains high-level insights into North America anti-hypertensive drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

North America anti hypertensive drugs market report size, by country, 2018-2030 (US$M)

North America Anti-hypertensive Drugs Market Share, 2023 & 2030 (US$M)

North America anti hypertensive drugs market report size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more